PROGYNY INC (PGNY) Stock Fundamental Analysis
NASDAQ:PGNY - Nasdaq - US74340E1038 - Common Stock - Currency: USD
Taking everything into account, PGNY scores 7 out of 10 in our fundamental rating. PGNY was compared to 102 industry peers in the Health Care Providers & Services industry. PGNY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. PGNY has a correct valuation and a medium growth rate. These ratings would make PGNY suitable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year PGNY was profitable.
PGNY had a positive operating cash flow in the past year.
Each year in the past 5 years PGNY has been profitable.
PGNY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
PGNY has a better Return On Assets (7.19%) than 90.20% of its industry peers.
PGNY has a Return On Equity of 11.24%. This is in the better half of the industry: PGNY outperforms 75.49% of its industry peers.
Looking at the Return On Invested Capital, with a value of 11.34%, PGNY belongs to the top of the industry, outperforming 86.27% of the companies in the same industry.
PGNY had an Average Return On Invested Capital over the past 3 years of 8.25%. This is in line with the industry average of 9.53%.
The last Return On Invested Capital (11.34%) for PGNY is above the 3 year average (8.25%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.19% | ||
| ROE | 11.24% | ||
| ROIC | 11.34% |
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
1.3 Margins
The Profit Margin of PGNY (4.33%) is better than 74.51% of its industry peers.
PGNY's Profit Margin has declined in the last couple of years.
The Operating Margin of PGNY (6.03%) is better than 63.73% of its industry peers.
PGNY's Operating Margin has improved in the last couple of years.
With a Gross Margin value of 21.99%, PGNY perfoms like the industry average, outperforming 46.08% of the companies in the same industry.
In the last couple of years the Gross Margin of PGNY has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.03% | ||
| PM (TTM) | 4.33% | ||
| GM | 21.99% |
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PGNY is creating some value.
PGNY has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, PGNY has more shares outstanding
There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 7.11 indicates that PGNY is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.11, PGNY belongs to the top of the industry, outperforming 93.14% of the companies in the same industry.
There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 7.11 |
ROIC/WACC1.24
WACC9.12%
2.3 Liquidity
PGNY has a Current Ratio of 2.39. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY has a better Current ratio (2.39) than 80.39% of its industry peers.
PGNY has a Quick Ratio of 2.39. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY's Quick ratio of 2.39 is amongst the best of the industry. PGNY outperforms 81.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.39 | ||
| Quick Ratio | 2.39 |
3. Growth
3.1 Past
PGNY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.56%.
Measured over the past years, PGNY shows a decrease in Earnings Per Share. The EPS has been decreasing by -4.77% on average per year.
The Revenue has grown by 9.46% in the past year. This is quite good.
The Revenue has been growing by 38.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-6.56%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)9.46%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%16.53%
3.2 Future
The Earnings Per Share is expected to grow by 32.47% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 8.94% on average over the next years. This is quite good.
EPS Next Y4.54%
EPS Next 2Y45.87%
EPS Next 3Y41.15%
EPS Next 5Y32.47%
Revenue Next Year6.5%
Revenue Next 2Y8.8%
Revenue Next 3Y9.97%
Revenue Next 5Y8.94%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
PGNY is valuated quite expensively with a Price/Earnings ratio of 37.18.
PGNY's Price/Earnings ratio is in line with the industry average.
The average S&P500 Price/Earnings ratio is at 26.03. PGNY is valued slightly more expensive when compared to this.
With a Price/Forward Earnings ratio of 17.47, PGNY is valued on the expensive side.
Based on the Price/Forward Earnings ratio, PGNY is valued a bit cheaper than the industry average as 62.75% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.94, PGNY is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.18 | ||
| Fwd PE | 17.47 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as PGNY.
Based on the Price/Free Cash Flow ratio, PGNY is valued cheaply inside the industry as 87.25% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.27 | ||
| EV/EBITDA | 19.18 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PGNY has a very decent profitability rating, which may justify a higher PE ratio.
PGNY's earnings are expected to grow with 41.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)8.18
PEG (5Y)N/A
EPS Next 2Y45.87%
EPS Next 3Y41.15%
5. Dividend
5.1 Amount
PGNY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
21.19
-0.68 (-3.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners99.16%
Inst Owner Change-8.92%
Ins Owners6.69%
Ins Owner Change4.71%
Market Cap1.82B
Analysts77.5
Price Target27.83 (31.34%)
Short Float %9.47%
Short Ratio4.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.62%
Min EPS beat(2)-11.77%
Max EPS beat(2)15%
EPS beat(4)1
Avg EPS beat(4)-4.37%
Min EPS beat(4)-19.12%
Max EPS beat(4)15%
EPS beat(8)5
Avg EPS beat(8)12.82%
EPS beat(12)9
Avg EPS beat(12)54.88%
EPS beat(16)13
Avg EPS beat(16)111.04%
Revenue beat(2)2
Avg Revenue beat(2)4.47%
Min Revenue beat(2)3.19%
Max Revenue beat(2)5.74%
Revenue beat(4)2
Avg Revenue beat(4)0.3%
Min Revenue beat(4)-5.35%
Max Revenue beat(4)5.74%
Revenue beat(8)4
Avg Revenue beat(8)-0.24%
Revenue beat(12)7
Avg Revenue beat(12)0.33%
Revenue beat(16)7
Avg Revenue beat(16)-0.81%
PT rev (1m)0%
PT rev (3m)37.41%
EPS NQ rev (1m)0.55%
EPS NQ rev (3m)15.93%
EPS NY rev (1m)-0.57%
EPS NY rev (3m)-3.08%
Revenue NQ rev (1m)1.27%
Revenue NQ rev (3m)4.66%
Revenue NY rev (1m)0.89%
Revenue NY rev (3m)5.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.18 | ||
| Fwd PE | 17.47 | ||
| P/S | 1.5 | ||
| P/FCF | 9.27 | ||
| P/OCF | 8.93 | ||
| P/B | 3.89 | ||
| P/tB | 4.12 | ||
| EV/EBITDA | 19.18 |
EPS(TTM)0.57
EY2.69%
EPS(NY)1.21
Fwd EY5.72%
FCF(TTM)2.29
FCFY10.78%
OCF(TTM)2.37
OCFY11.19%
SpS14.16
BVpS5.45
TBVpS5.14
PEG (NY)8.18
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.19% | ||
| ROE | 11.24% | ||
| ROCE | 14.82% | ||
| ROIC | 11.34% | ||
| ROICexc | 23.6% | ||
| ROICexgc | 26.56% | ||
| OM | 6.03% | ||
| PM (TTM) | 4.33% | ||
| GM | 21.99% | ||
| FCFM | 16.14% |
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
ROICexc(3y)19.18%
ROICexc(5y)17.15%
ROICexgc(3y)20.6%
ROICexgc(5y)18.86%
ROCE(3y)10.79%
ROCE(5y)10.01%
ROICexcg growth 3Y11.16%
ROICexcg growth 5Y-10.91%
ROICexc growth 3Y11.54%
ROICexc growth 5Y-2.19%
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
F-Score7
Asset Turnover1.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 207.4% | ||
| Cap/Sales | 0.61% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 265.01% | ||
| Profit Quality | 372.94% | ||
| Current Ratio | 2.39 | ||
| Quick Ratio | 2.39 | ||
| Altman-Z | 7.11 |
F-Score7
WACC9.12%
ROIC/WACC1.24
Cap/Depr(3y)177.5%
Cap/Depr(5y)150.16%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.39%
Profit Quality(3y)290.66%
Profit Quality(5y)196.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-6.56%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y4.54%
EPS Next 2Y45.87%
EPS Next 3Y41.15%
EPS Next 5Y32.47%
Revenue 1Y (TTM)9.46%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%16.53%
Revenue Next Year6.5%
Revenue Next 2Y8.8%
Revenue Next 3Y9.97%
Revenue Next 5Y8.94%
EBIT growth 1Y11.23%
EBIT growth 3Y27.82%
EBIT growth 5Y41.01%
EBIT Next Year25.81%
EBIT Next 3Y17.51%
EBIT Next 5Y15.16%
FCF growth 1Y79.62%
FCF growth 3Y93.67%
FCF growth 5YN/A
OCF growth 1Y80.28%
OCF growth 3Y90.18%
OCF growth 5YN/A